NextCell is pleased to announce that it has been to participate in the EIT Health Start.Smart.Global (SSG) programme. EIT Health is a Knowledge and Innovation Community established by the European Institute for Innovation & Technology (EIT), an independent EU body set up to promote innovation and entrepreneurship across Europe. The EIT Health Start.Smart.Global (SSG) programme, helps European life science SMEs optimise their market entries into the lucrative but challenging business environments of Japan and South Korea. NextCell, will receive expert advice on how to potentially enter the Japanese and Korean markets, either for
product commercialization or for further research & development projects. The preparation phase includes on-site training and various e-learning measures throughout the year.
NextCell’s rights issue was subscribed to 368 percent
The Board of NextCell Pharma AB (publ) (“NextCell” or “The Company”) today announces the outcome of the new share issue with preferential rights for the Company’s existing shareholders, which was approved by an extraordinary general meeting on May 24, 2019 The rights issue has been subscribed for at approximately SEK 91 million corresponding to a subscription rate of approximately 368 per cent and adds SEK 24.9 million to the company before deductions for issue costs.
Final patient treated in the phase II part of the ProTrans-1 trial
NextCell Pharma AB (NextCell) today treated the last diabetic patient in the phase II part of the ProTrans-1 trial. This means that all patients included in the clinical study will have been subject to a 12-month follow-up period before the efficacy and safety data will be available.
New collaboration and increased digital presence – Cellaviva is gearing for growth
NextCell Pharma AB (“NextCell”) today announces that they, via its biobank Cellaviva, have entered into partnership with Bonzun Health Information AB (“Bonzun”), who are providing the first global health app for pregnant women.
Anders Essen-Möller subscribes to his entire stakes in NextCell Pharma’s right issue
The two largest owners of NextCell Pharma AB (“NextCell” or “The Company”) Anders Essen-Möller and Diamyd Medical AB, fully subscribe for their respective shares in NextCells ongoing rights issue. This means that both parties consolidate their ownership interests and that Essen-Möllers owns in NextCell after the investments increase from approximately SEK 3.6 million to 6.0…
Selected to participate in the EIT Health Start.Smart.Global (SSG) programs.
NextCell Pharma AB (publ) (“NextCell”) has been chosen as one of a select group of companies to participate in the EIT Health Start.Smart.Global (SSG) programs. The program focuses on helping European life science SMEs enter into Japan and South Korea.
NextCell now has two parallel running clinical trials, ProTrans-1 and ProTrans-Repeat which was initiated today
NextCell Pharma AB (NextCell) announces that the initiation meeting for ProTrans-Repeat was held today at Karolinska University Hospital in Huddinge. ProTrans-Repeat is a completely independent trial and has no effect on the ProTrans-1 study. NextCell now has two ongoing clinical trials that run parallel and according to plan.
Rectification: Six out of nine patients in the first part of the phase I / II trial, ProTrans-1 have completed treatment
NextCell Pharma AB (NextCell) announces that six patients included in the dose escalation part of ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study.
NextCell Pharma invited speaker at the World Advanced Therapies & Regenerative Medicine Congress
NextCell Pharma AB (“NextCell”) and Cellaviva have been invited to attend and speak at the 14th annual World Advanced Therapies & Regenerative Medicine Congress, which is held at the Business Design Center, London 15 – 17 May.
ProTrans-Repeat, an approved clinical trial for repeated treatment of patients with diabetes
The Medical Products Agency has granted NextCell Pharma AB (“NextCell”) permission to conduct the new study, ProTrans-Repeat. The study is a continuation of ProTrans-1 where patients with type-1 diabetes who participated in the dose escalation part will be asked to participate in ProTrans-Repeat. The purpose is to investigate whether repeated treatment is safe and gives…
The Medical Products Agency grants NextCell permission to initiate the ProTrans-Repeat trial
NextCell Pharma AB (“NextCell”) today received a permit from the Medical Products Agency granting permission to initiate a new clinical trial, called ProTrans-Repeat. The trials is a continuation of the ongoing ProTrans-1 trial and of great importance to the further development of ProTrans. The goal for this study is to include those patients with type…
The NextCell Pharma AB board of directors proposes an Rights Issue of MSEK 24.9 and calls for an extraordinary general meeting
The Board of NextCell Pharma AB (publ) (“NextCell” or “the Company”) has decided to propose an extraordinary general meeting on May 24, 2019 to decide on a rights issue of shares (“Rights Issue”) totaling SEK 24.9 million. The rights issue is secured through subscription commitments and letter of intent of approximately 21 per cent and…
Discussions on a merger between NextCell AB and Idogen AB are suspended
The discussions that took place between the boards of NextCell Pharma AB (“NextCell”) and Idogen AB (“Idogen”) (together “The Companies”), regarding a possible merger, are suspended. Although the discussions have been characterized by pragmatism, but the boards of the companies have concluded that both companies will benefit from continuing to pursue their own activities.
Update regarding possible merger between NextCell Pharma AB and Idogen AB
Discussions between the boards of NextCell Pharma AB (publ) (“NextCell”) and Idogen AB (publ) (“Idogen”) (together “The companies”) regarding a possible merger, are still ongoing. Further information will be published no later than the opening of trading on Wednesday, 08 May 2019.
First Half (2018-09-01 till 2018-02-28) · Operating income amounted to SEK 508,7795 (391,204). · Operating result amounted to SEK -8,929,084 (-7,524,256). · Earnings per share* amounted to SEK -0.83 (-0.88). · Cash and bank amounted to SEK 6,886,879 (9,444,381). · Solidity** amounted to 87 (59) %. **Result per share: operating results divided by the average…